139 related articles for article (PubMed ID: 29803584)
1. Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:283-91.
Conteduca V; Gurioli G; De Giorgi U
Eur Urol; 2018 Sep; 74(3):e67-e68. PubMed ID: 29803584
[No Abstract] [Full Text] [Related]
2. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
Mehra N; Dolling D; de Bono J
Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
[No Abstract] [Full Text] [Related]
3. Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
Thiery-Vuillemin A; Fizazi K; Sartor O; Oudard S; Bury D; Ozatilgan A; Poole EM; Eisenberger M; de Bono J
Oncologist; 2021 Jul; 26(7):e1179-e1188. PubMed ID: 33904646
[TBL] [Abstract][Full Text] [Related]
4. Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
Montironi R; Cheng L; Scarpelli M; Cimadamore A; Montorsi F; Lopez-Beltran A
Eur Urol; 2019 Sep; 76(3):e69-e72. PubMed ID: 31176624
[No Abstract] [Full Text] [Related]
5. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Conteduca V; Lolli C; De Giorgi U
Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
[No Abstract] [Full Text] [Related]
6. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Rescigno P; de Bono JS
Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
[No Abstract] [Full Text] [Related]
7. Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Taneja SS
J Urol; 2018 Apr; 199(4):893-894. PubMed ID: 29642359
[No Abstract] [Full Text] [Related]
8. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.
O'Cathail M; Sundar S
Eur Urol; 2015 Jun; 67(6):e113-e114. PubMed ID: 25534667
[No Abstract] [Full Text] [Related]
9. Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?
van Soest RJ; Tombal B; Lolkema MP; de Wit R
Eur Urol; 2018 Sep; 74(3):292-293. PubMed ID: 29566958
[No Abstract] [Full Text] [Related]
10. Re: Axel Heidenreich, David Pfister. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol 2012;62:1201-4.
Brookman-May S; Tombal B; Joniau S
Eur Urol; 2013 Sep; 64(3):e62-4. PubMed ID: 23582882
[No Abstract] [Full Text] [Related]
11. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Ludmir EB; McCaw ZR; Wei LJ
Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
[No Abstract] [Full Text] [Related]
12. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Lu K
Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
[No Abstract] [Full Text] [Related]
13. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
von Eyben FE; Bauman G
Eur Urol; 2020 Mar; 77(3):e67-e68. PubMed ID: 31300234
[No Abstract] [Full Text] [Related]
14. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
Rocco B; Sighinolfi MC
Eur Urol; 2020 Mar; 77(3):e69. PubMed ID: 31151677
[No Abstract] [Full Text] [Related]
15. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
Shiota M; Yokomizo A
Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
[No Abstract] [Full Text] [Related]
16. Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
Tombal B
Eur Urol; 2014 Apr; 65(4):e56. PubMed ID: 24380648
[No Abstract] [Full Text] [Related]
17. Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
Dirix PR; Mercier C; Dirix LY
Eur Urol; 2019 Oct; 76(4):e101-e102. PubMed ID: 31255421
[No Abstract] [Full Text] [Related]
18. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB; Drake CG; Fizazi K
Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
[No Abstract] [Full Text] [Related]
19. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Caffo O; Maines F; Veccia A
Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376
[No Abstract] [Full Text] [Related]
20. Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Shen Y; Ye D
Eur Urol; 2012 Feb; 61(2):e3; author reply e4-5. PubMed ID: 21824719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
